NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
02 April 2025
| Name: | IMAGION BIOSYSTEMS LIMITED (IBX) |
| ISIN: | AU000000IBX6 |
| Date of Listing: | 22 June 2017 |
Stock Exchange Status: (updated daily)
This entity is currently listed and quoted on the Australian Securities Exchange.Legal Status: (updated monthly)
ACN: 616 305 027ABN: 42 616 305 027
Registration Date: 06 December 2016
Capital Gains Tax (CGT) Status: (updated at least quarterly)
To crystallise a capital gain or capital loss on your securities in this entity, you are able to sell your securities on-market in the normal manner. If you determine that the market in your securities is illiquid and you still wish to crystallise a capital gain or loss, kindly contact deListed at admin@delisted.com.au for suggestions as to how you might proceed.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
Boardroom Pty Ltd
Level 8, 210 George Street, Sydney NSW 2000
Tel : +61 2 9290 9600 or 1300 737 760
Fax : +61 2 9279 0664 or 1300 653 459
RegistryWebsite RegistryEmail
Expand this box to read and print
The suspension of trading in the securities of Imagion Biosystems Limited will be lifted immediately following lodgement of its Annual Report for the period ending 31 December 2023 and a release of an announcement relating to the appointment of a director. | 14/06/2024 |
The company releases the results of its meeting. | 31/05/2024 |
The company releases its AGM Investor Presentation. | 31/05/2024 |
The company releases its Chairman's Address to Shareholders. | 31/05/2024 |
The company releases its prospectus with a placement of 242,000 Convertible Notes with a face value of $1.00 per Convertible Note and a subscription price of $0.90909 to raise a maximum of approximately $220,000 before costs and grant of 2,048,122 Options. | 21/05/2024 |
The company will be re-instated to official quotation once a new Australian Director is appointed, following the release of its 2023 Annual Report. The ASX will re-instate IBX once it meets s201A(2) of the Corporationorafions Act. | 14/05/2024 |
The company releases its notification of cessation of securities. | 10/05/2024 |
The company releases its Appendix 4G and Corporate Governance Statement. | 10/05/2024 |
The company releases its 2023 Annual Report to shareholders. | 10/05/2024 |
The annual general meeting will be held at Level 25, 525 Collins Street, Melbourne VIC 3000 and virtually via the online platform https://www.web.lumiagm.com/367489986 on Friday 31 May 2024 at 10.00am (AEST). | 03/05/2024 |
The company lodges its Quarterly Activities/Appendix 4C Cash Flow Report. | 30/04/2024 |
The securities of the company will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Tuesday, 2 April 2024, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office on Thursday, 28 March 2024, and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed. | 02/04/2024 |
The securities of the company will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Tuesday, 2 April 2024, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office on Thursday, 28 March 2024, and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed. | 02/04/2024 |
The suspension of trading in the securities of Imagion Biosystems Limited will be lifted immediately, following the release by IBX of an announcement regarding a proposed capital raising. | 20/09/2018 |
The company announces a pro-rata non-renounceable rights issue to shareholders on the basis of 1 new share for every 2 imagion shares held as at 7.00pm (Melbourne time) Friday 28 September 2018. The funds will finance the company's first in-human study for metastatic breast cancer and for general working capital. The rights issue will be for an issue price of $0.04 per share to raise up to $4.3 million. There will be a shortfall facility to enable applications for additional shares. | 20/09/2018 |
The securities of Imagion Biosystems Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of IBX, pending the release of an announcement regarding a capital raising. | 17/09/2018 |
listed entity carried for record purposes only | 22/06/2017 |
The suspension of trading in the securities of Imagion Biosystems Limited will be lifted immediately following lodgement of its Annual Report for the period ending 31 December 2023 and a release of an announcement relating to the appointment of a director. | 14/06/2024 |
The company releases the results of its meeting. | 31/05/2024 |
The company releases its AGM Investor Presentation. | 31/05/2024 |
The company releases its Chairman's Address to Shareholders. | 31/05/2024 |
The company releases its prospectus with a placement of 242,000 Convertible Notes with a face value of $1.00 per Convertible Note and a subscription price of $0.90909 to raise a maximum of approximately $220,000 before costs and grant of 2,048,122 Options. | 21/05/2024 |
The company will be re-instated to official quotation once a new Australian Director is appointed, following the release of its 2023 Annual Report. The ASX will re-instate IBX once it meets s201A(2) of the Corporationorafions Act. | 14/05/2024 |
The company releases its notification of cessation of securities. | 10/05/2024 |
The company releases its Appendix 4G and Corporate Governance Statement. | 10/05/2024 |
The company releases its 2023 Annual Report to shareholders. | 10/05/2024 |
The annual general meeting will be held at Level 25, 525 Collins Street, Melbourne VIC 3000 and virtually via the online platform https://www.web.lumiagm.com/367489986 on Friday 31 May 2024 at 10.00am (AEST). | 03/05/2024 |
The company lodges its Quarterly Activities/Appendix 4C Cash Flow Report. | 30/04/2024 |
The securities of the company will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Tuesday, 2 April 2024, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office on Thursday, 28 March 2024, and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed. | 02/04/2024 |
The securities of the company will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Tuesday, 2 April 2024, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office on Thursday, 28 March 2024, and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed. | 02/04/2024 |
The suspension of trading in the securities of Imagion Biosystems Limited will be lifted immediately, following the release by IBX of an announcement regarding a proposed capital raising. | 20/09/2018 |
The company announces a pro-rata non-renounceable rights issue to shareholders on the basis of 1 new share for every 2 imagion shares held as at 7.00pm (Melbourne time) Friday 28 September 2018. The funds will finance the company's first in-human study for metastatic breast cancer and for general working capital. The rights issue will be for an issue price of $0.04 per share to raise up to $4.3 million. There will be a shortfall facility to enable applications for additional shares. | 20/09/2018 |
The securities of Imagion Biosystems Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of IBX, pending the release of an announcement regarding a capital raising. | 17/09/2018 |
listed entity carried for record purposes only | 22/06/2017 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 27/06/2024 | Brett Mitchell | 20,908 | $0.083 | $1,744 |
| 19/06/2024 | Brett Mitchell | 500,000 | $0.081 | $40,499 |
| 12/09/2022 | Dianne Angus | 243,000 | $0.037 | $8,991 |
| 24/11/2017 | Robert Proulx | 235,000 | $0.100 | $23,383 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Robert Proulx | Executive Chairman | 08/12/2016 |
| Melanie Leydin | Non Exec Director, Company Secretary | 13/05/2024 |
| Brett Mitchell | Non Exec Director | 14/06/2024 |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Michael Harsh | Non Exec Director | 02/03/2017 | 22/08/2024 |
| David Ludvigson | Non Exec Director | 10/03/2017 | 22/08/2024 |
| Mark Gerald Van Asten | Non Exec Director | 08/12/2016 | 22/08/2024 |
| Geoffrey Hollis | CFO, Company Secretary | 01/12/2020 | 10/05/2024 |
| Jovanka Naumoska | Non Exec Director | 08/12/2016 | 03/05/2024 |
| Dianne Angus | Non Exec Director | 08/05/2020 | 02/05/2024 |
| Isaac Bright | CEO | 20/06/2023 | 15/01/2024 |
| Brian Conn | CFO | 22/06/2017 | 01/08/2020 |
| Bronwyn Le Grice | Non Exec Director | 26/04/2018 | 31/03/2020 |
| John Hazle | Non Exec Director | 30/07/2018 | 27/06/2019 |
| Peter Di Chiara | Non Exec Director | 28/04/2017 | 26/04/2018 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.
